


PHARMACEUTICAL 2022

GlobeStar Therapeutics Corp Rank 473 of 475





PHARMACEUTICAL 2022

GlobeStar Therapeutics Corp Rank 473 of 475

The relative strengths and weaknesses of GlobeStar Therapeutics Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GlobeStar Therapeutics Corp compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 2,634% points. The greatest weakness of GlobeStar Therapeutics Corp is the variable Assets, Current, reducing the Economic Capital Ratio by 10,330% points.

The company's Economic Capital Ratio, given in the ranking table, is -11,005%, being 10,728% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	6.0
Cost of Goods Sold	2.4
Intangible Assets	0
Liabilities, Current	732
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	707
Other Liabilities	0
Other Net Income	0
Property and Equipment	0
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	9,092

Output Variable	Value in 1000 USD
Assets	6.0
Liabilities	732
Expenses	9,802
Stockholders Equity	-726
Net Income	-9,802
Comprehensive Net Income	-9,802
Economic Capital Ratio	-11,005%